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The gut is the most extensive, interactive, and complex interface between the human host and the envi-
ronment and therefore a critical site of immunological activity. Non-invasive methods to assess the host
response in this organ are currently lacking. Feces are the available analyte which have been in proximity
to the gut tissue.
We applied a method of concentrating host transcripts from fecal specimens using a existing bead-
based affinity separation method for nucleic acids and quantified transcripts using droplet digital PCR
(ddPCR) to determine the copy numbers of a variety of key transcripts in the gut immune system.
ddPCR compartmentalizes the reaction in a small aqueous droplet suspended in oil, and counts droplets
as either fluorescent or non-fluorescent. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
to normalize transcript concentration.
This method was applied to 799 fecal samples from rural Malawian children, and over 20,000 transcript
concentrations were quantified. Host mRNA was detected in >99% samples, a threshold for target detec-
tion was established at an average expression of 0.02 copies target/GAPDH, above which correlation coef-
ficient between duplicate measurements is >0.95. Quantities of transcript detected using ddPCR were
greater than standard qPCR. Fecal sample preservation at the time of collection did not require immediate
freezing or the addition of buffers or enzymes. Measurements of transcripts encoding immunoactive pro-
teins correlated with a measure of gut inflammation in the study children, thereby substantiating their
relevance. This method allows investigators to interrogate gene expression in the gut.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction Unfortunately, direct assessment of gut health is invasive andOptimal gut health is defined as the ability of the intestines to
absorb all necessary dietary nutrients while mounting appropriate
inflammatory responses to limit the dissemination of the microbes
from the lumen while averting chronic local or systemic inflamma-
tion. The many microbes in the gut are thought to modulate gut
health. Our awareness of the role of gut microbiota in gut health
has increased exponentially in the last 5 years. The most pervasive
condition associated with poor gut health worldwide is environ-
mental enteric dysfunction (EED), which is associated with stunt-
ing [1–3]. Stunting affects 25% of the world’s children, whose
capacity for physical work, neurocognitive function, linear growth
and immunocompetence are compromised [4]. Poor gut health has
also been implicated in gastrointestinal tract cancers [5,6],
autoimmune [7], mental health [8], neuro-psychological [9] and
cardiovascular [10] disorders.expensive. The most reliable methods to assess gut health involve
direct (endoscopic) visualization of the gut and biopsy, and the
dual sugar absorption test [11]. Endoscopy is a resource-
intensive procedure that is not well suited to mass screening, or
to frequent intra-host assessment. The dual sugar absorption test,
also known as the lactulose:mannitol (L:M) test, is administered
by orally ingesting a solution of both sugars, and collecting all
urine over a timed period of several hours. Lactulose, a disaccha-
ride, is absorbed only through disrupted cell junctions, while man-
nitol, a monosaccharide, is absorbed across cell membranes and
across cell junctions. Once absorbed these sugars are excreted
unmetabolized in the urine. Increased L:M is indicative of dis-
rupted architecture of the upper intestinal mucosa and poor gut
health [12]. This is a theoretically sound and often used test, but
does not provide information on mechanisms underlying increased
permeability.
Stool is an easily acquired, but understudied, analyte that con-
tains exfoliated enterocytes, representing gut mucosal tissue. Fecal
extractions have been rarely used to analyze expression of individ-
ual host transcripts by quantitative PCR (qPCR). qPCR for host fecal
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less than 1% of total fecal RNA, which is predominantly microbial
and ribosomal. mRNA in feces is also relatively degraded, and
quantification can be further hampered by co-extracted inhibitors.
Here we report an improved methodology to detect fecal host
mRNA using droplet digital PCR (ddPCR), as applied to stools from
rural Malawian children with varying states of gut health as deter-
mined by L:M testing.2. Materials and methods
2.1. Fecal samples
Fresh fecal samples were collected from 799 children aged 12–
61 months in rural Malawi who participated in one of 3 clinical
studies [13–15]. These children are from families of subsistence
farmers, consume water from wells or boreholes and live in
unelectrified mud huts. They are at high risk for the enteropathy
associated with stunting. All of the subjects completed a carefully
conducted L:M test with adequate urine collection and sugar
excretion [16].
Fresh stools were collected before completion of the L:M testing
using a small, clean non-absorbant, plastic diaper. The stools were
immediately transferred to cryovials and flash frozen in liquid
nitrogen, without buffers, enzymes or preservative solutions. Sam-
ples were transferred to a 80 C freezer and transported to Wash-
ington University (St. Louis, MO), where they were then processed
and analyzed for human fecal mRNA as outlined in Fig. 1 and
detailed below.
Among the many hundreds of stool samples collected, 16 were
divided into 6 aliquots and flash frozen immediately after, and 1, 2,
4, 8 and 24 h after passage. Storage prior to freezing was at ambi-
ent (Malawian) temperature, approximately 23–28 C.Fig. 1. Methodology used to isolate a2.2. Isolation of fecal RNA
Fecal nucleic acid extractions were prepared using NucliSENS
easyMAG system (bioMerieux, Durham, NC) and a modified ver-
sion the protocol of Agapova et al. [17]. Approximately 200–
300 mg of frozen stool and 8–10 disruption beads zirconium/silica
23 mm (Research Products International Corp.) was homogenized
in 1 ml of easyMAG lysis buffer using MP FastPrep-24 tissue
homogenizer (MP Biomedicals) (60 s, 6.5 m/s,) two times, and then
incubated (room temperature, 15 min). Debris was pelleted by
centrifugation (10 min, 14,800g), and the clarified supernatant
was loaded into wells of the easyMAG cartridges, avoiding visual
particulates. EasyMAG lysis buffer was added to fill the remaining
volume to 2 ml, 50 ll NucliSENS easyMAG magnetic silica were
added. Samples were then extracted following the manufacturer’s
instructions for Protocol A using the offboard lysis option.2.3. Droplet digital PCR detection of transcripts
Quantitative polymerase chain reaction assays were performed
using duplexed FAM and VIC TaqMan assays in a droplet digital
PCR system (QX100; Bio-Rad Laboratories, Inc, Hercules, CA) [18].
Duplicate reactions of 20 ll were prepared using 7.76 ll total
nucleic acids, 10 ll ddPCR Supermix for Probes (BioRad), 0.08 ll
SuperScript III Reverse Transcriptase (200 U/ll, Invitrogen Corpo-
ration, Carlsbad, CA), 0.16 ll RNase OUT (40 U/ll, Invitrogen),
and 1 ll of each 20  TaqMan Gene Expression Assay (Applied
Biosystems, Carlsbad, CA). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) assays were performed for each sample on each
plate for normalization of all other targets. PCR reactions were dis-
persed into droplets using the QX100 droplet generator per the
manufacturer’s instruction (BioRad Laboratories) and transferred
to a 96-well PCR plate. End point PCR was performed in a C1000
Touch thermal cycler (BioRad) with the following conditions:nd detect fecal host transcripts.
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Fig. 2. Detectability of human mRNA in fecal samples. GAPDH was assayed by droplet digital PCR in 3649 samples.
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Fig. 3. Reproductibility of the measurement of mRNA concentration isolated from
feces. The consistency of assay replicates was measured by r2 from 107 different
mRNA targets assayed in 20 samples/target relative to average expression levels
(target/GAPDH).
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98 C 100 and cooling to 4 C. The fluorescence of each droplet
was quantified in the QX100 droplet reader (BioRad Laboratories).
DNA extracted from Caco-2 cells was used as a negative control to
test the mRNA specificity of each probe analyzed.
2.4. Data processing
Absolute quantification was performed in QuantaSoft software
(BioRad, Santa Clara, CA). Thresholds were manually set to distin-
guish between positive and negative droplets. Samples with insuf-
ficient negative droplets for a clear baseline were excluded from
further analysis. Output from QuantaSoft included concentration
and droplet counts for each target in each well. The average con-
centration for duplicate wells was then calculated and normalized
to GAPDH in Access (Microsoft). Final expression results were
reported as Target/GAPDH ratios.
2.5. Comparison of ddPCR measurements with qPCR
Two fecal nucleic acid extractions were analyzed for interleuk-
in1b (IL1b) and GAPDH by both ddPCR and quantitative real time
PCR (qPCR). These 2 samples varied in quantity of human mRNA
in the extraction (indicated by GAPDH) and expression of IL1b
(indicated by IL1b/GAPDH), the relative quantity of IL1b to GAPDH
were chosen to vary by at least an order of magnitude, to represent
probes present in both high and low concentrations. Four serial 10-
fold dilutions of each sample were analyzed using Taqman assays
on both ddPCR (QX100 – BioRad laboratories Inc. Hercules, CA)
and qRT-PCR (ABI 7500 Fast Real time PCR system-Life Technolo-
gies, Waltham, MA) using equal input quantity of RNA for each
dilution. Target copy number calculations were determined for
each dilutions and comparisons were made between the concen-
tration of each target detected (copies/ll) as well as the expression
of IL1b (IL1/GAPDH).
2.6. Correlation of ddPCR measurements with L:M
Normalized expression values for mRNAs were analyzed for
Spearman’s correlation to concurrent L:M test results using SPSS
(IBM SPSS Statistics for Windows, Version 22.0).3. Results
3.1. Human mRNA detection
This study included analyses of over 20,000 individual host
transcript measurements in human feces. Despite the fact that
human protein coding targets account for a fraction of a percent
of fecal extracts, GAPDH was always detected in our fecal extrac-
tions. In 3649 samples assayed for GAPDH in duplicate wells with
at least 10,000 droplets/well, the median value was 143 copies/ll
GAPDH, with all samples having at least 1 copy/ll. About 80% of
the samples assayed had between 25 and 500 copies/ll GAPDH.
292 samples (8%) had GAPDH < 25 copies/ll (Fig. 2). DNA extracted
from Caco-2 cells was not detected in any of the samples, indicat-
ing that the assay is highly specific for RNA.
3.2. mRNA concentration isolated from feces can be estimated
reproducibly
Data for 107 different mRNA targets assayed in at least 20 sam-
ples/target in duplicate wells with a minimum of 10,000 droplets/
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tion to average expression levels (Target/GAPDH) (Fig. 3).3.3. Comparison of ddPCR and qPCR detection
Two samples assayed for IL1b and GAPDH in four serial 10-fold
dilutions demonstrated a linear relationship over a 1000 fold vari-
ation in concentration, and that ddPCR detected more copies/ll of
both mRNA targets (Fig. 4). The relative abundance of IL1b toS a m p le 1
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3.4. Degradation of mRNA when held at an ambient temperature prior
to flash freezing
GAPDH concentrations were unchanged in identical samples
allowed to set at ambient conditions up through 4 h prior to flash
freezing, on average they were 336 ± 287 copies/ll, but after 8 h
declined to 242 ± 223 copies/ll and to 205 ± 181 copies/ll afterT -PCR
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Fig. 5. Stability of mRNA when samples are held at room temperature prior to flash
freezing. The stability was measured as the TLR-4/GAPDH ratio in 16 samples at 0, 1,
2, 4, 8 and 24 h prior to flash freezing.
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(TLR4) concentrations for the 16 subjects from whom stool ali-
quots were frozen after storage at ambient conditions for up to
24 h are portrayed in Fig. 5. The median coefficient of variationTable 1
Summary of 18 transcripts correlated with L:M.
Gene
symbol
Gene function
ACP1 Acts on tyrosine phosphorylated proteins, low-MW aryl phosphates and n
acyl phosphates. Isoform 3 does not possess phosphatase activity
AQP9 Forms a channel with a broad specificity. Mediates passage of non-charge
carbamides, polyols, purines, and pyrimidines, whereas amino acids, cycli
excluded
BIRC3 Regulates caspases and apoptosis, modulates inflammatory signaling and
kinase signaling and cell proliferation, as well as cell invasion. Acts as an
ligase
CD53 Mediates signal transduction promoting cell development. Complexes wit
in this gene result in immunodeficiency
CDX1 Caudal type homeobox 1. Plays a role in the terminal differentiation of th
DECR1 Auxiliary enzyme of beta-oxidation. It participates in the metabolism of un
CoA esters. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA t
CoA
DEFA6 Has antimicrobial activity against Gram-negative and Gram-positive bacte
against infection with HIV-1
HLADRA Binds peptides derived from antigens that access the endocytic route of an
and presents them on the cell surface for recognition by the CD4 T-cells
IFI30 Lysosomal thiol reductase that reduces protein disulfide bonds. Facilitates
unfolding of proteins destined for lysosomal degradation. Plays an import
processing
LYZ Lysozyme has primarily a bacteriolytic function; those in tissues and bod
with the monocyte-macrophage system and enhance the activity of immu
MUC12 Mucin 12. Codes for key protein in mucous layer. Involved in epithelial ce
modulation, signaling and epithelial cell growth regulation. Stimulated by
cytokines
PIK3AP1 Signaling adapter that contributes to B-cell development. Links Toll-like r
PI3K activation, preventing excessive inflammatory cytokine production. A
cells
REG1A Acts as an inhibitor of spontaneous calcium carbonate precipitation. Asso
brain and pancreas regeneration
REG3A Bactericidal C-type lectin which acts exclusively against Gram-positive ba
bacterial killing by binding to surface-exposed carbohydrate moieties of p
S100A8 Calprotectin, a calcium- and zinc-binding protein which plays a prominent
of inflammatory processes and immune response. Induces neutrophil che
SELL Cell surface adhesion protein. Promotes initial tethering and rolling of leu
SI Sucrase isomaltase. A disaccharidase that plays an important role in carbo
Isomaltase activity is specific for a-1,4- and a-1,6-oligosaccharides
TNF Cytokine that binds to TNFRSF1A/TNFR1. Secreted by macrophages, poten
cell death. Induces IL-12 production in dendritic cells
1 Expressed as copies/copy GAPDH.in TLR4 measurements was 16%, with 14/16 CV measurements
being <26%.
3.5. Correlation between ddPCR measures of inflammatory transcripts
and L:M measurements
A set of transcripts was chosen for study because of the known
association of their cognate proteins with small bowel inflamma-
tion, enteric infections or tissue expression in the small bowel, in
view of the fact that EED is a small bowel disorder (Supplemental
Data 1, Supplemental Data 2). 114/184 (62%) transcripts chosen
were detectable in quantities >0.002 copies/copy GAPDH. Among
the 53 transcripts tested in at least 70 children, 18 correlated with
L:M (Table 1).
4. Discussion
We present a robust and reproducible method that uses ddPCR
to measure individual host transcripts in feces, in which GAPDH is
detected in >99% of thousands of samples tested, and which is
more sensitive than qPCR. Moreover, it is not dependent on imme-
diate flash freezing, which is considered the gold standard for stool
mRNA preservation [19]. This analytical method successfully iden-
tified specific transcripts that are associated with EED, a common
cause of gut inflammation in the developing world.Transcript
Concentration1Median (25th,
75th percentiles)
Spearman’s r
with L:M
P value
of r
atural and synthetic 0.007 (0.005, 0.011) 0.104 0.043
d solutes including
c sugars, and ions are
0.065 (0.019, 0.150) 0.299 0.01
immunity, mitogenic
E3 ubiquitin-protein
0.119 (0.075, 0.192) 0.125 0.005
h integrins. Mutations 0.071 (0.031, 0.172) 0.316 0.006
e intestine 0.026 (0.016, 0.042) 0.157 <0.001
saturated fatty enoyl-
o yield trans-3-enoyl-
0.035 (0.022, 0.047) 0.220 0.043
ria. Protects cells 0.038 (0.015, 0.096) 0.138 0.009
tigen presenting cells 0.176 (0.103, 0.279) 0.136 0.002
the complete
ant role in antigen
0.168 (0.081, 0.288) 0.264 0.024
y fluids are associated
noagents
0.083 (0.040, 0.137) 0.297 0.011
ll protection, adhesion
inflammatory
0.321 (0.162, 0.541) 0.271 0.021
eceptor signaling to
ctivates natural killer
0.048 (0.022, 0.121) 0.249 0.029
ciated with intestinal, 0.040 (0.018, 0.103) 0.188 <0.001
cteria and mediates
eptidoglycan
0.049 (0.019, 0.086) 0.262 0.011
role in the regulation
motaxis and adhesion
0.386 (0.154, 1.169) 0.096 0.025
kocytes in endothelia 0.009 (0.003, 0.038) 0.295 0.008
hydrate digestion. 0.017 (0.008, 0.036) 0.100 0.006
t pyrogen, promotes 0.004 (0.002, 0.008) 0.153 <0.001
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sion levels >0.02 target/GAPDH. At this cutoff, 86% of targets have
r2 values >0.9, as opposed to only 14% of targets with lower expres-
sion levels. Therefore, when testing new targets it is advisable first
to test a small number of samples and determine average expres-
sion before proceeding with large numbers of samples. Extremely
low expression targets (<0.001 Target/GAPDH) can still be accu-
rately quantified by concentrating samples or by increasing the
number of wells/assay and merging the wells using QuantaSoft
software (BioRad, Santa Clara, CA). However these measures may
be impractical when routinely assaying large numbers of samples.
We had access to liquid nitrogen for flash freezing fecal sam-
ples, but our data show that ambient temperatures for 24 h with-
out preservatives did not permit within sample mRNA degradation.
This corroborates the finding of Bennett, et al., in newborn stool
(2009). A 34% reduction in GAPDH was seen over the 24 h period,
so for samples with intermediate concentrations of GAPDH < 50 -
copies/ll immediate cryopreservation might be advisable.
The correlations identified between 18 host transcripts and a
known gut inflammatory gastrointestinal condition, EED, demon-
strate that this method can be used in clinical investigation. A
panel of small number of host inflammatory transcripts measured
by ddPCR may serve as a surrogate for the L:M test or marker of
disease progression. S100A8, which is correlated with L:M, is the
host transcript that corresponds to the protein calprotectin; a fecal
protein is used to clinically assess bowel inflammation. Calpro-
tectin is one of a very few proteins that can remain intact to allow
for reproducible detection as it passes through gastrointestinal
tract with its many microbes that secrete proteases. Unlike fecal
proteins, about 62% of host transcripts were detected fecal sam-
ples. Protein detection in stool has been described as ‘often quali-
tative and variably sensitive’ [20]. By measuring fecal transcripts,
which can be amplified and thus detected when present in smaller
quantities, gut health may be more reliably assessed and better
understood in the future.
Despite the attributes of this technique, there are some caveats
to our findings. This ddPCR method will need to be tested in addi-
tional sets of subjects to determine its suitability for detection of
fecal host transcripts across other disorders and populations. In
samples from healthy adults with good gut health, detection of
mRNA might well be more difficult, because of the relative paucity
of host transcripts. When measuring transcripts by ddPCR, two
probes with different fluorescent labels are placed in the same
well. Interactions between probes in the same well may occur
and introduce measurement variation. However, we did not
observe this among the pairings used. Measurement of host tran-
scripts in feces has previously been reported in a few studies using
PCR, but is not in widespread use as analytical method, so this
work is an extension of previous investigations [21–26]. These pre-
vious studies were done with a small number of samples, and in
many samples no host mRNA was detected. Our method offers
improved target detection sensitivity, which we attribute to our
isolation method and application of ddPCR. We also recommend
setting a minimum threshold of 25 copies/ll of GAPDH in every
sample to provide a reliable measurement of targets of interest,
most of which are expressed at levels well under that of GAPDH.
Assay replicates are highly consistent for mRNA targets with
expression levels above 0.02 copies/ll target/GAPDH. We also
observed greater numbers of transcript in samples by ddPCR than
by qPCR, consistent with previous work [27]. This might be the
result of reduced PCR inhibition because of compartmentalization
of reactions by the oil medium or by underestimation due to reli-
ance on a standard curve in RT-PCR.
In summary, quantification of host inflammatory transcripts in
stool could detect mRNA biomarkers of gut disease. Host tran-
scripts in feces may find application to diagnose conditions wherethe presence of both certain pathogen and a host inflammatory
response is required to produce illness, such as Clostridium difficile
infections [26]. Future research is needed to realize this potential.
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